SOUTH SAN FRANCISCO -- (BUSINESS WIRE) -- iPierian, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced today that it will make a presentation of a preclinical study from its Tau antibody program at the Society for Neuroscience annual meeting taking place November 9-13, 2013, in San Diego, CA.
The presentation will describe in vivo efficacy results in a study of IPN002, the parental version of the lead candidate IPN007. IPN007 is iPierian’s lead antibody program, representing a new approach to Alzheimer’s disease and other tauopathies by targeting a novel form of secreted Tau, to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression.
Oral presentation details:
Tuesday, November 12, 2013, 2:30 pm PST, “Effects of a Tau therapeutic antibody on the ISF/CSF levels of secreted Tau in the P301L mouse model,” Irene Griswold-Prenner, PhD, iPierian, Inc., Nanosymposium Session 598, Alzheimer’s Disease: Tau Biology, 1:00-3:45 pm PST.
The Tau protein functions to stabilize microtubules and is abundant in neurons in the central nervous system. Aberrantly modified forms of tau have been correlated with dementias such as Alzheimer’s disease (AD), Frontotemporal Dementia, PSP, and other tauopathies. Aberrant Tau accumulation correlates with the disease progression of dementia, in contrast to amyloid beta which maximally deposits years prior to dementia and therefore may be too late to intervene against. Animal models of AD have recently suggested that Tau can spread from one neuron to another, transmitting pathological Tau and correlating with the progression of AD pathology in humans. It is possible that therapeutics which slow the spread of Tau may also slow the clinical course of AD and related tauopathies.
iPierian is a biotechnology company developing novel therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau protein for treatment of Alzheimer’s disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). The company’s lead antibody, IPN007, represents a new approach to Alzheimer’s by targeting a novel form of secreted Tau protein that is differentially regulated in Alzheimer’s disease patients, to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression. iPierian’s monoclonal antibody program for Tau is based on novel Tau discoveries made using the company’s proprietary induced pluripotent stem cell (iPSC) technology. iPierian is located in South San Francisco, California. For more information, please visit www.ipierian.com.